Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination intervention used in the ECSMOKE clinical trial (NCT03630614) for smoking cessation. It consists of varenicline, a small-molecule partial agonist of the alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptor, and a nicotine-free electronic cigarette (ECwoN) which serves as a behavioral and sensory substitute for smoking. Varenicline works by reducing nicotine cravings and withdrawal symptoms while blocking the reinforcing effects of nicotine. The nicotine-free e-cigarette addresses the behavioral aspects of smoking addiction without delivering nicotine. This combination is being evaluated as a comparator to nicotine-containing e-cigarettes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on electronic cigarette without nicotine + varenicline.